APO RESEARCH · REPORT
Measles, Mumps, Rubella, and Varicella Combined Vaccine
Selected research
Industry Research
Measles, Mumps, Rubella, and Varicella Combined Vaccine Industry Research Report 2026
Market perspective
The global Measles, Mumps, Rubella, and Varicella Combined Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Measles, Mumps, Rubella, and Varicella Combined Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Measles, Mumps, Rubella, and Varicella Combined Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Measles, Mumps, Rubella, and Varicella Combined Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Measles, Mumps, Rubella, and Varicella Combined Vaccine include Merck & Co, Kangtai Bio and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Measles, Mumps, Rubella, and Varicella Combined Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Measles, Mumps, Rubella, and Varicella Combined Vaccine Market by Company
Merck & Co
Kangtai Bio
GlaxoSmithKline
Measles, Mumps, Rubella, and Varicella Combined Vaccine Segment by Type
Inactivated Vaccine
Live Attenuated Vaccine
Measles, Mumps, Rubella, and Varicella Combined Vaccine Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Measles, Mumps, Rubella, and Varicella Combined Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Measles, Mumps, Rubella, and Varicella Combined Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Measles, Mumps, Rubella, and Varicella Combined Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Measles, Mumps, Rubella, and Varicella Combined Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Measles, Mumps, Rubella, and Varicella Combined Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Measles, Mumps, Rubella, and Varicella Combined Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Measles, Mumps, Rubella, and Varicella Combined Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Inactivated Vaccine
- Live Attenuated Vaccine
Applications
- Hospital
- Centers for Disease Control and Prevention
- Others
Companies covered
- Merck & Co
- Kangtai Bio
- GlaxoSmithKline
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Size (2021-2032)
- 2.2.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales (2021-2032)
- 2.2.3 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Average Price (2021-2032)
- 2.3 Measles, Mumps, Rubella, and Varicella Combined Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Inactivated Vaccine
- 2.3.3 Live Attenuated Vaccine
- 2.4 Measles, Mumps, Rubella, and Varicella Combined Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Centers for Disease Control and Prevention
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Measles, Mumps, Rubella, and Varicella Combined Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Measles, Mumps, Rubella, and Varicella Combined Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Measles, Mumps, Rubella, and Varicella Combined Vaccine, Established Date
- 3.9 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck & Co
- 4.1.1 Merck & Co Company Information
- 4.1.2 Merck & Co Business Overview
- 4.1.3 Merck & Co Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck & Co Measles, Mumps, Rubella, and Varicella Combined Vaccine Product Portfolio
- 4.1.5 Merck & Co Recent Developments
- 4.2 Kangtai Bio
- 4.2.1 Kangtai Bio Company Information
- 4.2.2 Kangtai Bio Business Overview
- 4.2.3 Kangtai Bio Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Kangtai Bio Measles, Mumps, Rubella, and Varicella Combined Vaccine Product Portfolio
- 4.2.5 Kangtai Bio Recent Developments
- 4.3 GlaxoSmithKline
- 4.3.1 GlaxoSmithKline Company Information
- 4.3.2 GlaxoSmithKline Business Overview
- 4.3.3 GlaxoSmithKline Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlaxoSmithKline Measles, Mumps, Rubella, and Varicella Combined Vaccine Product Portfolio
- 4.3.5 GlaxoSmithKline Recent Developments
5 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Scenario by Region
- 5.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Region: 2027-2032
- 5.3 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Region: 2027-2032
- 5.4 North America Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Facts & Figures by Country
- 5.4.1 North America Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Facts & Figures by Country
- 5.7.1 South America Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Measles, Mumps, Rubella, and Varicella Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Measles, Mumps, Rubella, and Varicella Combined Vaccine Value Chain Analysis
- 8.1.1 Measles, Mumps, Rubella, and Varicella Combined Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Measles, Mumps, Rubella, and Varicella Combined Vaccine Production Mode & Process
- 8.2 Measles, Mumps, Rubella, and Varicella Combined Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Measles, Mumps, Rubella, and Varicella Combined Vaccine Distributors
- 8.2.3 Measles, Mumps, Rubella, and Varicella Combined Vaccine Customers
9 Global Measles, Mumps, Rubella, and Varicella Combined Vaccine Analyzing Market Dynamics
- 9.1 Measles, Mumps, Rubella, and Varicella Combined Vaccine Industry Trends
- 9.2 Measles, Mumps, Rubella, and Varicella Combined Vaccine Industry Drivers
- 9.3 Measles, Mumps, Rubella, and Varicella Combined Vaccine Industry Opportunities and Challenges
- 9.4 Measles, Mumps, Rubella, and Varicella Combined Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst